Tvardi Therapeutics (TVRD) Non-Current Deffered Revenue (2013 - 2019)

Tvardi Therapeutics has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $6.1 million in Q2 2019.

• Quarterly Non-Current Deffered Revenue fell 79.92% year-over-year to $6.1 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $6.1 million (down 79.92% YoY) and the FY2019 annual result came in at $9.6 million, changed N/A from the prior year.
• Non-Current Deffered Revenue slipped to $6.1 million in Q2 2019 per TVRD's latest filing, from $9.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $30.3 million in Q2 2018 and troughed at $585000.0 in Q4 2015.
• A 5-year average of $3.6 million and a median of $1.6 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2018 and 2019: Non-Current Deffered Revenue soared 1838.52% in 2018, then plunged 79.92% in 2019.
• Over 5 years, Non-Current Deffered Revenue stood at $585000.0 in 2015, then jumped by 168.38% to $1.6 million in 2016, then increased by 9.43% to $1.7 million in 2017, then declined by 9.08% to $1.6 million in 2018, then surged by 289.56% to $6.1 million in 2019.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $6.1 million, $9.6 million, and $1.6 million for Q2 2019, Q1 2019, and Q4 2018 respectively.